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Chinese herbal medicinal (CHM) extracts from fourteen plants were investigated in cell-based in vitro assays for their eﬀect on
nuclear factor κB( N F - κB), a key regulator of inﬂammation, as well as on peroxisome proliferator-activated receptors (PPARs)
being key regulators of genes involved in lipid and glucose metabolism. 43% of the investigated CHMs showed NF-κB inhibitory
and 50% PPARα and PPARγ activating eﬀects. Apolar extracts from cortex and ﬂos of Albizia julibrissin Durazz. and processed
rhizomes of Arisaema sp. and Pinellia ternata (Thunb.) Breit. that eﬀectively inhibited TNF-α-induced NF-κB activation and dose-
dependently activated PPARα and PPARγ were further investigated. Bioassay-guided fractionation and analysis by GC-MS led to
the identiﬁcation of fatty acids as PPAR agonists, including linoleic and palmitic acid.
1.Introduction
Herbal medicines are an important part of Traditional
Chinese Medicine (TCM) of which the medical use and pro-
cessingmethodsarewelldocumented.Traditionalprocessing
methods (pao zhi) are important to enhance the eﬃcacy
and/or to reduce the toxicity of crude herbal products [1].
Chinese herbal medicine (CHM) encompasses over 11,000
species of medicinal plants and is a valuable source [2]
for the identiﬁcation of biologically active natural products.
Investigationofthemoleculartargetsandmechanisticaction
of CHMs and their single compounds is currently a central
task in TCM research [3]. Thanks to advances in molecular
biology, reﬁned bioassays are now available which enable
rapid screening of natural products for bioactivity towards
speciﬁc targets [4]. In this study, extracts of diﬀerent polarity
from CHMs of fourteen plant species were tested for a
potential inhibition of TNF-α-induced NF-κB activation and
an agonistic activity towards PPARα and PPARγ.T h eC H M s
were selected in cooperation with Chinese partners [5]. This
in-housecollectionofCHMs(Table 1)wasalreadyexamined
earlier based on their traditional use against insomnia
and anxiety regarding a putative modulation of the GABAA
receptor[6].ThelistedCHMsare,however,alsotraditionally
prescribed as single herbs as well as in formulations for
clearing heat anddrying dampness, among others. Therefore,
to gain insight into possible multi-target eﬀects of the
individual CHMs, this study examined their inﬂuence on
the nuclear factor κB( N F - κB) pathway and peroxisome
proliferator-activated receptors (PPARs), which are impor-
tant drug targets with regard to inﬂammation and metabolic
dysfunction.
The NF-κB signaling pathway is a key regulator of
inﬂammation. Inﬂammatory stimuli such as tumor necrosis
factor alpha (TNF-α), infectious agents (lipopolysaccharide
(LPS)), injury, and other stressful conditions activate the
NF-κB signal transduction pathway. Thereby, activation of
the IKK complex leads to phosphorylation and subsequent
proteasomal degradation of IκB proteins. NF-κB dimers
are translocated to the nucleus and bind to κBp r o m o t o r2 Evidence-Based Complementary and Alternative Medicine
Table 1: The plant species and the respective Chinese herbal medicines tested for potential activation of human PPARα and PPARγ and
inhibition of TNF-α-induced NF-κBa c t i v i t y .
Plant species Family Plant part Pin Yin CHM no.
Albizia julibrissin Durazz. Fabaceae Cortex h´ eh u¯ an p´ ı1 a
Flos h´ eh u¯ an hu¯ a1 b
Arisaema sp. Araceae Rhizoma∗ zh` ıt i¯ an n´ an x¯ ıng 2a
Rhizoma∗∗ zh` ıt i¯ an n´ an x¯ ıng 2b
Arnebia/Lithospermum sp. Boraginaceae Radix z˘ ıcˇ ao 3
Atractylodes macrocephala Koidz. Asteraceae Rhizoma b´ ai zh´ u4
Cnidium monnieri (L.) Cuss. Apiaceae Fructus sh´ ec h u´ ang z˘ ı5
Dimocarpus (Euphoria) longan Lour. Sapindaceae Arillus long yˇ an r` ou 6
Forsythia suspensa (Thunb.) Vahl. Oleaceae Fructus li´ an qi` ao 7
Juncus eﬀusus L. Juncaceae Medulla d¯ eng x¯ ın cˇ ao 8
Lilium sp. Liliaceae Bulbus bˇ ai h´ e9
Lophatherum gracile Brongn. Poaceae Herba d` an zh´ uy` e1 0
Nelumbo nucifera Gaertn. Nelumbonaceae Plumula li´ an z˘ ıx ¯ ın 11
Pinellia ternata (Thunb.) Breit. Araceae Rhizoma b` an xi` a 12a
Rhizoma∗∗ zh` ıb` an xi` a 12b
Polygonum multiﬂorum Thunb. Polygonaceae Caulis sh˘ ou w¯ ut´ eng 13
Tribulus terrestris L. Zygophyllaceae Fructus c` ıj ´ ıl ´ ı1 4
Processed by cooking ∗ or soaking ∗∗ in water with alum (KAl(SO4)2·12H2O).
sites resulting in the transcription of proinﬂammatory target
genes [7, 8]. Inhibitors of NF-κB signaling are promising
candidates for both the prevention and therapy of (chronic)
inﬂammation. Terpenoids, such as parthenolide, are known
to be eﬀective natural NF-κB inhibitors [9].
PPARs regulate the expression of genes involved in
lipid and glucose metabolism and homeostasis in a ligand-
dependent manner [10]. In the activated form, PPARα
promotes mainly fatty acid (FA) catabolism, and PPARγ
enhancesinsulinsensitivityandlipidstorage[11,12].PPARα
and PPARγ agonism is also linked to the suppression of pro-
inﬂammatorygenes,forexample,viaaninterferencewiththe
NF-κB signaling pathway [13, 14]. Synthetic PPAR agonists
(ﬁbratesandthiazolidinediones)bindPPARswithhighaﬃn-
ity. They, however, show signiﬁcant dose limiting adverse
sideeﬀects.Naturalproductswererevealedtobeapromising
source of safer PPARα and PPARγ dual agonists or partial
PPAR modulators [15–18].
In our study, extracts of selected CHMs that exhibited
a signiﬁcant activity towards PPARs or NF-κB were further
subjected to dose-response studies and bioassay-guided
f r a c t i o n a t i o n .T h e s es e l e c t e dC H M sw e r ec o r t e xa n dﬂ o so f
Albizia julibrissin Durazz. as well as processed and crude
rhizomes of Arisaema sp. and Pinellia ternata (Thunb.)Breit.
Traditionally, A. julibrissin cortex and ﬂos are used in CHM
to treat insomnia and injuries and to calm the mind.T h e
rhizomes of Arisaema sp. and P. ternata are toxic in their
crude form and therefore traditionally processed (Table 1).
Processed rhizomes of Arisaema sp. and P. ternata CHMs are
eﬀective in removing damp-phlegm such as in convulsions
and spasms in the intestines [19, 20]. The dried, pulverized
crude rhizomes from P. ternata are used externally to treat
swellings. Bioactive compounds were isolated, analyzed, and
characterized by mass spectrometry and NMR.
2.MaterialsandMethods
2.1. Materials. Human embryonic kidney (HEK) 293 cells
stably transfected with an NF-κB-responsive luciferase
reporter were purchased from Panomics (Fremont, CA,
USA) and 3T3-L1 preadipocytes and HEK293 cells from the
American Type Culture Collection (Manassas, VA, USA).
The PPARluciferasereporter construct(tk-PPREx3-luc)and
the expression plasmids for PPARα and PPARγ (pCMX-
mPPARα and pCMX-mPPARγ) were a gift from Professor
Ronald M. Evans (Howard Hughes Medical Institute, La
Jolla, CA, USA). The plasmid encoding enhanced green ﬂu-
orescent proteins (pEGFP-N1) was obtained from Clontech
(Mountain View, CA, USA). Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 4.5g/L glucose was purchased
from Lonza Group AG (Basel, Switzerland) and fetal bovine
serum (FBS) from Invitrogen (Lofer, Austria). GW7647 and
troglitazone were purchased from Cayman Europe (Tallinn,
Estonia) and 2-deoxy-D-(1H3)-glucose from Perkin Elmer
(Waltham, MA, USA). For extraction, fractionation, and
isolation by silica column chromatography (CC), solvents of
highest available purity were used (VWR, Vienna, Austria).
All other chemicals were obtained from Sigma-Aldrich
(Vienna, Austria).
2.2. Plant Materials. Material of the CHMs no. 1–14 were
purchased from Plantasia (Oberndorf, Austria) (see Table 1)
[19,20],exceptofno.12awhichwaspurchasedfromSichuan
Neautus Traditional Chinese Medicine Co., Ltd (Chengdu,Evidence-Based Complementary and Alternative Medicine 3
China). Voucher specimens are deposited at the Department
of Pharmacognosy, University of Vienna, encoded with the
CHM numbers shown in Table 1.
2.3. Extraction and Fractionation. 50g of each of the CHMs
nos. 1a, 1b, 2a, 3–11, 12b, 13, and 14 was soaked in 500mL
petroleum ether (PE) for 10min, and extracted under reﬂux
for 30min. The obtained extracts were ﬁltered and evapo-
rated to dryness. The remaining drug material was air-dried
overnight and extracted each with 500mL of ethyl acetate
(EtOAc), methanol (MeOH), and distilled water likewise,
whereas the water extract was lyophilized. All following
extractions were performed at 150 bar and 40◦C using an
ASE200acceleratedsolventextractorandasolventcontroller
(Dionex, Sunnyvale, CA, USA). With the ASE every ca. 10g
of pulverized plant material in a capsule was extracted three
times with 22mL of solvent (66mL/ca. 10g). The scheme of
each run of extraction was as follows: 5min heating, 2min
static at 150 bar and 40◦C, 10s ﬂushing and 60s purging. For
CHMs nos. 2b, 12a, and 12b out of 50g each DCM dry
extract yields of 0.4–0.7% were obtained and for no. 1b a
yield of 2.9% (See Schemes 1 and 2 in Supplementary Mate-
rial available online at doi:10.1155/2012/983023).
Forbioassay-guidedfractionation,1.4kgofCHMsno.1a
and 1.9kg of no. 2a were pulverized and extracted by DCM
and subsequently by MeOH. 68g DCM extract (4.7% yield)
and 92g MeOH extract (6.6% yield) were obtained of no.
1a. 12.1g DCM (0.6% yield) and 10.7g MeOH (0.8% yield),
out of 1.4kg of the material already extracted by DCM, were
obtained of no. 2a. The dried extracts of no. 2a were sub-
jected to silica CC with Silica Gel 60 (particle size of 0.063–
0.200mm, Merck, Darmstadt, Germany). The column with
D C Me x t r a c tw a se l u t e dw i t hC H C l 3 :MeOH:H 2O98:2:1
to 60:38:8.5 to obtain eight fractions (D1–D8). From
fractions D8, cerebrosides were isolated by silica CC eluting
with CHCl3 :MeOH:H 2O 65:25:4. Cerebrosides were also
detected in CHMs no. 12a and b from P. ternata.1 5 go f
DCM extract of no. 1a was fractionated using VLC (Vacuum
Liquid Chromatography) using Silica Gel 60 (particle size
of 0.063–0.200mm, Merck, Darmstadt, Germany) as solid
phase. The silica column was eluted subsequently with PE,
DCM (twice), EtOAc, MeOH, and 90% MeOH (3 L per
solvent) under reduced pressure. Thereby 12mg PE extract,
963mg extract from the ﬁrst 3L eluted with DCM (DCM-I),
776mg from the next 3L eluted with DCM (DCM-II), 6.90g
EtOAc extract, 4.08g MeOH extract, and ﬁnally 170mg
extractelutedwith90%MeOHwereobtainedasdryextracts.
Betulinicacid(12mg)wasisolatedfromEtOAcVLCfraction
of the DCM extract from no. 1a. A mixture of trihydroxy
and epoxy-dihydroxy fatty acid methyl esters (FAMEs)
(8mg) and α-spinasterol-3-O-β-D-glucopyranoside (61mg)
was isolated from the crude MeOH extract by repeated silica
CC eluting with CHCl3 :MeOH:H 2Oa n dn-hexane:EtOAc
gradients. The compounds in the mixture could be sep-
arated by GC-MS and were identiﬁed based on resem-
blance with the fragmentation in EI MS reported by Ham-
berg [21] as methyl 9,10,13-trihydroxy-11-octadecenoate,
methyl 9,12,13-trihydroxy-11-octadecenoate, and methyl
9,10-epoxy-13-hydroxy-11-octadecenoate. Their hydroxy-
lated FA derivatives were prepared by basic hydrolysis with
0.1M NaOH (15min RT) of the hydroxylated FAMEs and
acidiﬁcation with 0.1M HCl/MeOH. For biological testing
from all corresponding samples, always dry material was
dissolved in DMSO.
2.4. NMR Analysis. A l l1 D( 1Ha n d13C) and 2D (COSY,
NOESY, HMQC, and HMBC) NMR spectra were recorded
on a Bruker Avance 500 NMR spectrometer. Betulinic acid
was dissolved in CDCl3 (99.96 atom%D) and α-spinasterol-
3-O-β-D-glucopyranoside in d5-pyridine (99.96 atom%D).
The 1Ha n d13CN M Rs p e c t r aw e r eo p e r a t e da t5 0 0a n d
125MHz, respectively. 13Ca n d1H NMR data of both were
consistentwiththeliteraturevaluesforbetulinicacid[22,23]
and α-spinasterol-3-O-β-D-glucopyranoside [24, 25].
2.5. Analysis of Active Compounds by GC-MS. The investi-
gated extracts and fractions were dissolved to 5mg/mL in
DCM, and 200μL of the dissolved sample was transferred
t oaG C - M Sv i a l ,t ow h i c h5 0μLo fT M S Hw a sa d d e d .T h e
mixture with a concentration of 4mg/mL was shaken for
30s. A GCMS-QP2010 gas chromatograph mass spectrome-
terwasutilized(ShimadzuScientiﬁcInstruments,Columbia,
MD, USA). Helium 5.0 was used as carrier gas, and the
column ﬂow was set at a constant value of 1.7mL/min.
T h ec o l u m nu s e dw a saZ e b r o nZ B - 56 0 m× 0.25mm
(inner diameter), 0.25μm (ﬁlm thickness) (Phenomenex,
Torrance, CA, USA). The software used was Lab Solutions
GC-MS (version 2.50 SU3, Shimadzu). 1μL of sample was
injected of the prepared solutions with a split 1:10, and
analysis was performed in the EI mode (70eV, 250◦Ci o n
source temperature). The injection temperature was 270◦C.
A method with a temperature gradient from 120◦Ct o
320◦C in 40min and 5min hold on 320◦C was applied
for analysis. A mixture of trihydroxy- and epoxy-hydroxy
FAMEs from no. 1a was derivatised by BSTFA-TMCS (99:1)
for 30min at 50◦C and detected by GC-MS in the same
conditions as above. The analyses were performed on an
Agilent Technologies 6890N Network GC equipped with an
Agilent Technologies 5973 inert mass selective detector and
a Combi PAL autosampler (CTC Analytics). The column
used was a DB-5 with dimensions of 30m × 0.25mm (inner
diameter), 0.23μm (ﬁlm thickness) (Agilent Technologies).
The software used was MSD Chemstation 2004.
2.6. NF-κB Transactivation Assay. HEK 293 cells, stably
transfected with as NF-κB-responsive luciferase reporter
(Panomics, Fremont, CA, USA), were seeded in 10cm dishes
and transfected with 5μg pEGFP-N1 (Clontech, Mountain
View, CA, USA). Six hours later, cells were transferred to 96-
well plates and incubated overnight (5% CO2,3 8 ◦C). On
the next day, the medium was exchanged with a serum-
free DMEM, and cells were treated with the indicated
extracts or fractions. The solvent vehicle (0.1% DMSO)
served as negative control and 5μM parthenolide as positive
control. After one hour, cells were stimulated with 2ng/mL
human recombinant TNF-α for 6h, then the medium
was removed, and cells were lysed. The luminescence of4 Evidence-Based Complementary and Alternative Medicine
Table 2: Screening of Chinese herbal medicines for agonistic activity towards PPARα and PPARγ and inhibition of TNF-α-induced NF-κB
activity in vitro.P E= petroleum ether, EtOAc = ethyl acetate, MeOH = methanol. Dry material from all test samples was dissolved in DMSO
at a concentration of 10mg/mL and tested at a ﬁnal concentration of 10μg/mL. Regarding PPARs: no activation compared to control (0.1%
DMSO): −;1 . 5 -t o2 - f o l da c t i v i t yc o m p a r e dt oc o n t r o l( P<0.05): +; more than 2-fold of the control (P<0.05): ++. Regarding NF-κB:
inhibition in the range of 0–50% compared to the vehicle-treated control (0.1% DMSO): −; 50–80% inhibition (P<0.05): +; over 80%
inhibition (P<0.05): ++. At least three independent experiments were performed with every sample, and statistical analysis was performed
by ANOVA.
Plant species CHM no. Extract PPARα PPARγ NF-κB
activation activation inhibition
Albizia julibrissin Durazz.
1a
PE ++ ++ +
EtOAc ++ ++ +
MeOH + + +
H2O −−+
1b
PE + + −
EtOAc ++ ++ +
MeOH −−−
H2O −− ++
Arisaema sp. 2a
PE ++ + +
EtOAc −−−
MeOH −−−
H2O −−−
Arnebia/Lithospermum sp. 3
PE −−−
EtOAc −−−
MeOH −−−
H2O −−−
Atractylodes macrocephala Koidz. 4
PE −−−
EtOAc −−−
MeOH −−−
H2O −−−
Cnidium monnieri (L.) Cuss. 5
PE −−−
EtOAc ++ + +
MeOH −−−
H2O −−−
Dimocarpus (Euphoria) longan Lour. 6
PE −−−
EtOAc −−−
MeOH −−−
H2O −−−
Forsythia suspensa (Thunb.) Vahl. 7
PE −−+
EtOAc −− ++
MeOH −−−
H2O −−−
Juncus eﬀusus L. 8
EtOAc −− ++
MeOH −−+
H2O −−−
Lilium sp. 9
EtOAc + −−
MeOH −−−
H2O −−−
Lophatherum gracile Brongn. 10
PE + −−
EtOAc + −−
MeOH −−−
H2O −−−
Nelumbo nucifera Gaertn. 11
PE −−−
EtOAc −−−
MeOH −−−
H2O −−−Evidence-Based Complementary and Alternative Medicine 5
Table 2: Continued.
Plant species CHM no. Extract PPARα PPARγ NF-κB
activation activation inhibition
Pinellia ternata (Thunb.) Breit. 12b
PE ++ + +
EtOAc −−−
MeOH −−−
H2O −−−
Polygonum multiﬂorum Thunb. 13
PE −−−
EtOAc −−−
MeOH −−−
H2O −−−
Tribulus terrestris L. 14
PE −−−
EtOAc + + −
MeOH −−−
H2O −−−
the ﬁreﬂy luciferase and the ﬂuorescence of the enhanced
green ﬂuorescent protein (EGFP) were quantiﬁed on a
GeniosProplatereader(Tecan,Austria).Theluciferasesignal
derived from the NF-κB reporter was normalized with the
EGFP-derived ﬂuorescence to account for diﬀerences in the
cell number.
2.7. PPAR Luciferase Reporter Gene Assay. The PPAR-lucif-
erase reporter gene assay was performed as previously de-
scribed [26]. HEK293 cells were transiently transfected with
aP P A R α or PPARγ receptor expression plasmid, a reporter
plasmid (tk-PPREx3-luc), and a green ﬂuorescent protein
plasmid (pEGFP-N1) as an internal control. The cells were
harvested 6h after the transfection and reseeded in 96-well
plates (5 × 104 cells/well). In the initial tests, cells were
treated with 10μg/mL of the indicated extracts. In the dose-
response experiments, cells were treated with 0, 3, 27 or
81μg/mL of the DCM extracts of CHMs nos. 1a, 1b, 2a,
2b, 12a, and 12b. To account for potential eﬀects of the
solvent, 0.1% DMSO served as vehicle control. As positive
controls, 50nM GW7647 and 5μM troglitazone were used
to activate PPARα and PPARγ, respectively. Treated cells
were incubated for 18h. After cell lysis, the luminescence
of the ﬁreﬂy luciferase and the ﬂuorescence of EGFP were
quantiﬁed on a GeniosPro plate reader (Tecan, Salzburg,
Austria). The luminescence signals were normalized to the
EGFP-derived ﬂuorescence to account for diﬀerences in cell
number or transfection eﬃciency.
2.8. Statistical Analysis. Statistical analysis was performed
using Prism Software (ver. 4.03; GraphPad Software Inc.,
San Diego, CA). Data were normalized to DMSO-treated
control of which the mean value was set as 1.0. The data
shown represent arithmetic mean and standard deviation
of 3-4 independent experiments. Statistical signiﬁcance was
determined by a one-way analysis of variance combined with
a Dunnett’s Multiple Comparison posttest. Results with P<
0.05 were considered signiﬁcant.
3. Results and Discussion
In this study, extracts of important Chinese herbal medicines
fromfourteendiﬀerentplantspecies(Table 1)wer etestedfor
their potential to inhibit NF-κB and/or to activate PPARα
and PPARγ.
Extracts of CHMs of six out of fourteen plant species
reduced TNF-α-induced NF-κB activity signiﬁcantly (P<
0.05) (Table 2). In fact, this is the ﬁrst report of a signiﬁcant
NF-κB inhibitory activity of extracts from A. julibrissin,
Arisaema sp., J. eﬀuses,a n dP. ternata.Am o d e ra t e( s e ee x p l a -
nation accompanying Table 2) reduction of TNF-α-induced
NF-κBa c t i v i t y( P<0.05) was found for the PE, EtOAc, and
MeOH extracts of A. julibrissin no.1a and the EtOAc extract
of no. 1b and C. monnieri no. 5, and PE extracts of Arisaema
sp. no. 2a and P. ternata no. 12b. The EtOAc extracts of
F. suspensa no. 7, J. eﬀusus no. 8, and the aqueous extract
of A. julibrissin no. 1b exhibited an especially strong ability
(see explanation accompanying Table 2) to inhibit NF-κB
activity. Betulinic acid was isolated from the DCM extract
of the bark of A. julibrissin no. 1a [27]. Many terpenoids,
including betulinic acid, are reported to eﬀectively inhibit
NF-κBsignaling[9,28].However,weneitherdetectedNF-κB
inhibitionnorPPARαandPPARγ activationbybetulinicacid
inconcentrationsupto30μMexcludingbetulinicacidasone
of the main active principles in our cellular models. Osthole
might in part have contributed to the observed activities of
the EtOAc extract of C. monnieri no. 5 [29–31].
WhentestingforaPPARαandPPARγ agonisticactivity,a
signiﬁcant eﬀect (P<0.05) was observed for apolar extracts
of seven out of the fourteen plants used as CHM (Table 2).
Moderate to strong PPARα and PPARγ activity was observed
for apolar extracts from A. julibrissin no. 1a and 1b, Arisaema
sp.no.2a,C.monnierino.5,P. ternata no.12aandT. terrestris
no. 14 (P<0.05). Apolar extracts of Lilium sp. no. 9 and L.
lophatherum no. 10 activated PPARα moderately (P<0.05).
Previously, a saponin from fruits of T. terrestris [32, 33]a n d
a q u e o u se x t r a c t so fa r i l l u sf r o mD. longan and rhizomes of6 Evidence-Based Complementary and Alternative Medicine
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Arisaema sp. no. 2a (DCM) Arisaema sp. no. 2b (DCM)
A.julibrissin no. 1a (DCM) A.julibrissin no. 1b (DCM)
3 μg/mL 9 μg/mL 27 μg/mL 81 μg/mL
DMSO 3 μg/mL 9 μg/mL 27 μg/mL 81 μg/mL
DMSO 3 μg/mL 9 μg/mL 27 μg/mL 81 μg/mL DMSO 3 μg/mL 9 μg/mL 27 μg/mL 81 μg/mL
DMSO 3 μg/mL 9 μg/mL 27 μg/mL 81 μg/mL
DMSO 3 μg/mL 9 μg/mL 27 μg/mL 81 μg/mL
Figure 1: Dose-response experiments with DCM extracts of CHMs of A. julibrissin no. 1a and b, Arisaema s p .n o .2 aa n db ,a n dP. ternata
no. 12a and b. HEK293 cells were transiently transfected with the expression plasmid for PPARα or PPARγ, the reporter plasmid pPPRE-
tk3x-luc, and the internal control plasmid (EGFP). The transiently transfected cells were incubated for 18h with 3, 9, 27, and 81μg/mL
of each indicated extract. Furthermore, the cells were similarly incubated with 0.1% DMSO (negative control), 50nM GW7647 (PPARα
agonist, activated PPARα 2.5–3.5 fold but not PPARγ), or 5μMt r o g l i t a z o n e( P P A R γ agonist, activated 3.5–6.5 fold PPARγ but not PPARα)
as positive controls (not shown). Luciferase activity and ﬂuorescence intensity were measured. Results are presented as mean ± SD, (n = 4).
Signiﬁcantly diﬀerent from the negative control (ANOVA), ∗P<0.05; ∗∗P<0.01.
P. ternata [34–36] were reported to increase PPARα and
PPARγ gene expression levels.
A selection of CHMs with strong activity, namely, A.
julibrissin no. 1a and b, Arisaema sp. no. 2a and b and of
P. ternata no. 12a, and b were further studied. The DCM
extracts of no. 1a, 1b, 2a, 2b, 12a, and 12b showed a signiﬁ-
cant dose-dependent increase of PPARα and PPARγ activity
(P<0.01) (Figure 1), whereby those of nos. 1a and 1b fromEvidence-Based Complementary and Alternative Medicine 7
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Figure 2: Comparison of the PPARα-a n dP P A R γ-activating potential of the VLC fractions petroleum ether (PE), DCM-I and -II, and
ethyl acetate extract (EtOAc) of the DCM extract from A. julibrissin no. 1a (a) and the DCM fractions D1-8 from Arisaema s p .n o .2 a .( b ) .
HEK293 cells, transiently transfected with expression plasmids for PPARα or PPARγ, luciferase reporter (tk-PPREx3-luc), and EGFP as
internal control, were incubated for 18h with 10μg/mL of the indicated fraction, solvent vehicle (0.1% DMSO, negative control), and 50nM
GW7647 (PPARα agonist) or 5μMt r o g l i t a z o n e( P P A R γ agonist) as positive control. Luciferase activity and ﬂuorescence intensity were
measured. Results are presented as mean ± SD (n = 4). Signiﬁcantly diﬀerent from the negative control (ANOVA), ∗P<0.05; ∗∗P<0.01.
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Figure 3: Comparative analysis by GC-MS of the DCM-I and -
II and EtOAc VLC fractions (1μLo f4m g / m Li nD C M )f r o mt h e
mother DCM extract of CHMs nos. 1a of A. julibrissin.F A M E s
formed from the present FAs after derivatisation by TMSH were
detected by GC-MS on a Zebron ZB-5 column (60m × 0.25mm,
0.25μm) (Phenomenex) with a temperature gradient of 120◦C-
320◦C in 40min and 5min hold; carrier gas: helium; ﬂow rate:
1.7mL/min. Ion source: EI 70eV, 250◦C. The following FAs were
identiﬁed by GC-MS with a relative content (%) in each enriched
extract given in the order DCMI; DCMII and EtOAc: (1) palmitic
acid (2.9; 37; 23%), (2) linoleic acid (4.5; 1.0; 47%), (3) 9-
octadecenoic acid (3.3; 5.1; 4.4%), (4) oleic acid (—; 3.8; 5.8%),
(5) octadecanoic acid (3.3; 9.4; 2.2%), (6) docosanoic acid (—; 4.5;
1.7%), and (7) tetracosanoic acid (—; 2.3; 3.0%).
A. julibrissin and no. 2a from Arisaema sp. were most potent.
Lossofactivityat81μg/mLoftheseextractswaspossiblydue
to toxicity or unspeciﬁc inhibitory action.
Bioassay-guided fractionation showed that the fraction
“DCM-II” (see Section 2) of the DCM extract from A.
julibrissin no. 1a signiﬁcantly activated PPARα by 3.5-fold
(±0.31, P<0.01) and PPARγ by 2.8-fold (±0.28, P<0.01)
(compared to DMSO as solvent control). The EtOAc VLC
fraction signiﬁcantly activated PPARα by 2.9-fold (±0.52,
P<0.01) and PPARγ by 2.5-fold (±0.19, P<0.01). The
apolar fraction “D6” from Arisaema sp. no. 2a signiﬁcantly
activated PPARα by 2.2-fold (±0.10, P<0.01) and PPARγ
by 1.5-fold (±0.06, P<0.01) (Figure 2). GC-MS analysis
after derivatisation revealed that the VLC fractions of A.
julibrissin no. 1a (DCM) and fraction “D6” from Arisaema
sp.no.2acontainedmainlyfattyacids(FAs),suchaspalmitic
acid (16:0), stearic acid (18:0), and linoleic acid (18:2)
(Figures 3 and 4) that are known as PPAR agonists [11].
13-Phenyltridecanoic acid (13:0) was found as a compound
speciﬁc for aroids [37]. Especially polyunsaturated FAs acti-
vate PPARs potently [38]. Wolfrum et al. reported palmitic
acid (18:0), linoleic acid (18:2), oleic acid (18:1), and
s t e a r i ca c i d( 1 8 : 0 )t oa c t i v a t eP P A R α by 2.5-, 4.6-, 3.5-,
and 2-fold, respectively [39]. The processing might have
inﬂuenced availability of FA from rhizomes of P. ternata.
The concentration of FAs detected was higher in the DCM
extract of processed rhizomes of P. ternata (no. 12b) than
in that of the crude rhizomes (no. 12a) (Figure 4). This was
in line with the observation that the DCM extract of the
processed 12b was PPARα and PPARγ active at slightly lower
concentration than that of the crude rhizomes (no. 12a)
(Figure 1). The activation of PPARα by fraction “D6” may be
attributedlargelytopalmiticacid,whichishighlyenrichedin
fraction “D6” reaching 61% of the total content (Figure 4).
α-Spinasterol-3-O-β-D-glucopyranoside from A. julibrissin
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Figure 4: Comparative analysis by GC-MS of fraction D6 from the DCM extract of the CHM no. 2a from Arisaema sp. with DCM extracts
from CHMs no. 2a and b of Arisaema sp. and no. 12a and b from P. ternata (1μLo f4m g / m Li nD C M ) .F A M E sf o r m e df r o mt h ep r e s e n tF A s
after derivatisation by TMSH were detected by GC-MS as in Figure 3. The following FAs were identiﬁed by GC-MS with a relative content
(%) in each enriched extract given in the order of D6, CHM no. 2a, 2b, 12a and 12b: (1) nonanedioic acid (1.1; 4.1; 3.4;—; 3.8%), (2)
tetradecanoic acid (1.0; 2.1; 1.0; —; 0.4%), (3) pentadecanoic acid (2.4; 1.5; 0.8;—; 0.9), (4) 9-hexadecenoic acid (1.5; 1.7; 0.4;—; 0.1%), (5)
palmitic acid (61; 39; 74; 30; 37%) (6) linoleic acid (6.5; 8.9; 0.5; 36; 6.6%), (7) 9-octadecenoic acid (4.2; 8.2; 4.6; 17; 9.2%), (8) oleic acid
(2.9; 1.6; 1.0;—; 2.6%), (9) octadecanoic acid (8.5; 4.5; 3.4; 2.6; 4.4%), (10) 13-phenyltridecanoic acid (3.4; 3.9; 0.5; 0.1; 2.6%), and (11)
docosanoic acid (0.2; 0.9; 0.7;—; 0.3).
of Arisaema sp. and P. ternata were tested; however, did not
show agonistic activity towards PPARα-a n dP P A R γ-activity
in vitro.
It became further evident that the content of the FAs
present in “D6” was also high in the DCM extracts from
CHMs from Arisaema sp. and P. ternata (Figure 4), especially
of palmitic acid (30%–74%). The CHMs of T. terrestris and
C. monnieriwere previously described to contain FAs includ-
ingpalmiticacid,stearicacid,oleicacid,andlinoleicacid[19,
32]. Besides common FAs, trihydroxy- and epoxy-hydroxy
FAMEs and α-spinasterol-3-O-β-D-glucopyranoside were
isolated from the MeOH extract of A. julibrissin no. 1a.
Although mono- and dihydroxylated FAs are natural PPARγ
agonists [40], trihydroxy- and epoxy-hydroxy FAMEs as well
as their FA derivatives, identiﬁed by GC-MS [21], lacked
PPARαandPPARγ activityinvitrointhisstudy.Interestingly,
chronic exposure to high levels of palmitic acid and stearic
acid, identiﬁed as one of the main active principles in this
study, are associated with lipotoxicity or insulin resistance,
themaincausativefactoroftype2diabetesandthemetabolic
syndrome [33, 39]. However, unsaturated free FAs, such as
linoleicacidandoleicacid,donotpromoteinsulinresistance
[41]. In contrast, even a protective eﬀect of oleic acid against
palmitate-induced insulin resistance in L6 rat myotubes has
been demonstrated [42]. Moreover, FAs have recently been
identiﬁed as rather potent inhibitors of PTP1B, the main
negative regulator of insulin and leptin signaling [43]. Thus,
the impact of FAs on health and disease seems to highly
depend on duration of exposure, concentration of the FA,
or the degree of saturation.
4. Conclusion
In this study, extracts from CHMs were tested for a putative
PPARα-o rP P A R γ-activating and NF-κB-inhibiting eﬀect.
Out of the fourteen plant species of which extracts were
tested, 43% exhibited NF-κB inhibitory and 50% PPAR
activating eﬀe c t s .T h ea p o l a rP P A Ra c t i v ee x t r a c t sa n d
enriched fractions from ﬂos and cortex of A. julibrissin and
rhizomes of Arisaema sp. and P. ternata mainly contained
fatty acids as PPAR-agonists, including palmitic acid, linoleic
acid, oleic acid, and stearic acid. The outcome of this study
contributes to the molecular understanding and explanation
of some eﬀects elicited by extracts of these three traditional
Chinese herbs by revealing PPAR activation due to the
present fatty acids.
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